As genomic profiling cases may be biased toward more aggressive or refractory breast cancers and this cohort was restricted to cases with available ER status, the distribution of RET alterations may be skewed and limited in generalization to specific breast cancer subtypes. This evidence concerns the gene RET and breast cancer.